1550P Survival outcomes in phase I trial combining the STING agonist ulevostinag ± pembrolizumab in solid tumors (MK1454-001).
Saved in:
| Title: | 1550P Survival outcomes in phase I trial combining the STING agonist ulevostinag ± pembrolizumab in solid tumors (MK1454-001). |
|---|---|
| Authors: | Llop Serna, S.1 (AUTHOR), Jimenez Labaig, P.1 (AUTHOR), Micheletto, I.1 (AUTHOR), Rullan Iriarte, A.J.2 (AUTHOR), Ouali, K.3 (AUTHOR), Champiat, S.4 (AUTHOR), Romano, E.5 (AUTHOR), Bastien, E.6 (AUTHOR), Golan, T.7 (AUTHOR), Gomez-Roca, C.A.8 (AUTHOR), Perets, R.9 (AUTHOR), Wong, D.J.10 (AUTHOR), Harrington, K.J.11 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS926-S926. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2181 |
